PHASE I TRIAL OF D1694, AN INHIBITOR OF THYMIDYLATE SYNTHASE

本I期研究旨在定义MTD（最大耐受剂量） D1694在儿科患者中的应用叶酸的类似物已经被 已成功用于癌症治疗40多年。 经典抗叶酸剂的潜在作用机制，如 甲氨蝶呤（MTX）是他们的能力，阻止从头合成的 DNA的嘌呤和嘧啶核苷酸前体，主要由 抑制二氢叶酸还原酶（DHFR）。胸苷酸合成酶（TS）， 一种酶，其通过在还原酶中利用5，10-CH 2FH 4而起作用， 脱氧尿苷酸（dUMP）的甲基化，是从头 因此是叶酸的潜在靶点 类似物我们正在所有中心招募患者，因此，完成研究 很快

This phase I study is designed to define the MTD (maximum tolerated dose) of D1694 in pediatric patients. Analogs of folic acid have been successfully used for the treatment of cancer for more than 40 years. The underlying mechanism of action for classical antifols such as methotrexate (MTX) is their ability to block the denovo synthesis of purine and pyrimidine nucleotide precursors of DNA, primarily by inhibiting dihydrofolate reductase (DHFR). Thymidylate synthase (TS), an enzyme which acts by utilizing 5, 10-CH2FH4 in the reductive methylation of deoxyuridylate (dUMP),is required for the de novo synthesis of thymidylate and is thus a potential target of folic acid analogs. We are enrolling patients in all centers thus, finish the study soon.